Tumour Registry Breast Cancer (TMK)
|Study Design:||Observational Model: Cohort
Time Perspective: Prospective
|Official Title:||Clinical Registry to Present Treatment and Sequences of Treatments in Routine Practice in Germany|
- Course of Antineoplastic Treatment [ Time Frame: 5 years ] [ Designated as safety issue: No ]
|Study Start Date:||February 2007|
|Estimated Study Completion Date:||December 2020|
|Estimated Primary Completion Date:||June 2019 (Final data collection date for primary outcome measure)|
The TMK is a prospective, longitudinal, nation wide cohort study with the purpose to record information on the antineoplastic treatment of breast cancer in Germany. The registry will follow patients for up to five years. It will identify common therapeutic sequences and changes in the treatment of the disease. At inclusion, data in patient characteristics, comorbidities, tumor characteristics, biomarker testing and previous treatments are collected. During the course of observation data on all systemic treatments, radiotherapies, surgeries, and outcome are documented.
The impact of nutrition (MaNut) and physical activity (MaNut) on the course of the adjuvant disease will be examined, as well as long-term effects of adjuvant treatment (MaTox) and the multiple patient-reported outcomes (MaLife).
Please refer to this study by its ClinicalTrials.gov identifier: NCT01351584
|Study Chair:||Hans Tesch, MD|